The relationship between atopic dermatitis (AD) severity, sleep disturbance (SD), and health-related outcomes is not fully elucidated.
Objective
The aim of the study was to determine the prevalence of SD in adult AD and its relationship with AD severity and health outcomes among the US population.
Methods
A cross-sectional, US population–based survey study of 2893 adults was performed.
Results
Among adults meeting the UK Diagnostic Criteria for AD, 255 (40.7%) reported 1 or more, 67 (11.1%) reported 3 to 4, and 57 (9.5%) reported 5 to 7 nights of SD in the past week; 475 (79.7%) reported at least some trouble sleeping in the past 3 days. Moderate and severe Patient-Oriented Scoring AD, Patient-Oriented Eczema Measure, and Numeric Rating Scale–itch and Numeric Rating Scale–skin pain scores were associated with more severe SD compared with those without AD. More frequent and severe SDs were associated with higher Dermatology Life Quality Index, lower 12-item Short-Form Health Survey, and higher Hospital Anxiety and Depression Scale (HADS) scores. Significant mediation by SD severity was observed between Patient-Oriented Eczema Measure and Numeric Rating Scale–itch with Dermatology Life Quality Index, 12-item Short-Form Health Survey physical and mental component scores, HADS-anxiety and HADS-depression scores, diagnosed anxiety, and heart disease.
Conclusions
Atopic dermatitis and AD severity are associated with SDs. Sleep disturbances considerably impact quality of life and other health outcomes in adults with AD.
Get full access to this article
View all access options for this article.
References
1.
FishbeinAB, VitaternaO, HaughIM, et al.Nocturnal eczema: review of sleep and circadian rhythms in children with atopic dermatitis and future research directions. J Allergy Clin Immunol, 2015; 136(5):1170–1177.
2.
LiJC, FishbeinA, SingamV, et al.Sleep disturbance and sleep-related impairment in adults with atopic dermatitis: a cross-sectional study. Dermatitis, 2018; 29(5):270–277.
3.
SilverbergJI, GargNK, PallerAS, et al.Sleep disturbances in adults with eczema are associated with impaired overall health: a US population-based study. J Invest Dermatol, 2015; 135(1):56–66.
4.
YuSH, AttarianH, ZeeP, et al.Burden of sleep and fatigue in US adults with atopic dermatitis. Dermatitis, 2016; 27(2):50–58.
5.
SilverbergJI, GelfandJM, MargolisDJ, et al.Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study. Ann Allergy Asthma Immunol, 2018; 121(3):340–347.
6.
ChengBT, SilverbergJI. Depression and psychological distress in US adults with atopic dermatitis. Ann Allergy Asthma Immunol, 2019; 123(2):179–185.
7.
PatelKR, ImmaneniS, SingamV, et al.Association between atopic dermatitis, depression, and suicidal ideation: a systematic review and meta-analysis. J Am Acad Dermatol, 2019; 80(2):402–410.
8.
SilverbergJI, GelfandJM, MargolisDJ, et al. Symptoms and diagnosis of anxiety and depression in atopic dermatitis in U.S. adults. Br J Dermatol, 2019; 181(3):554–565.
9.
YuSH, SilverbergJI. Association between atopic dermatitis and depression in US adults. J Invest Dermatol, 2015; 135(12):3183–3186.
10.
BrunnerPM, SilverbergJI, Guttman-YasskyE, et al.Increasing comorbidities suggest that atopic dermatitis is a systemic disorder. J Invest Dermatol, 2017; 137(1):18–25.
11.
SilverbergJ, GargN, SilverbergNB. New developments in comorbidities of atopic dermatitis. Cutis, 2014; 93(5):222–224.
12.
SilverbergJI, GelfandJM, MargolisDJ, et al.Association of atopic dermatitis with allergic, autoimmune, and cardiovascular comorbidities in US adults. Ann Allergy Asthma Immunol, 2018; 121(5):604–612 e603.
13.
SilverbergJI, GreenlandP. Eczema and cardiovascular risk factors in 2 US adult population studies. J Allergy Clin Immunol, 2015; 135(3):721–728 e726.
14.
StromMA, FishbeinAB, PallerAS, et al. Association between atopic dermatitis and attention deficit hyperactivity disorder in U.S. children and adults. Br J Dermatol, 2016; 175(5):920–929.
15.
SilverbergJI.Association between childhood eczema and headaches: an analysis of 19 US population-based studies. J Allergy Clin Immunol, 2016; 137(2):492–499 e495.
16.
SilverbergJI, PallerAS. Association between eczema and stature in 9 US population-based studies. JAMA Dermatol, 2015; 151(4):401–409.
17.
McKenzieC, PallerAS, FishbeinA, et al.Association between the longitudinal course of AD, sleep disturbance, and overall health in US children. J Allergy Clin Immunol Pract, 2020; 8(2):812–814.e811.
18.
GargN, SilverbergJI. Association between eczema and increased fractures, bone or joint injury in adults: a US population-based study. JAMA Dermatol, 2015; 151(1):33–41.
19.
StromMA, SilverbergJI. Eczema is associated with childhood speech disorder: a retrospective analysis from the National Survey of Children's Health and the National Health Interview Survey. J Pediatr, 2016; 168:185–192.e184.
20.
Chiesa FuxenchZC, BlockJK, BoguniewiczM, et al.Atopic dermatitis in America study: a cross-sectional study examining the prevalence and disease burden of atopic dermatitis in the US adult population. J Invest Dermatol, 2019; 139(3):583–590.
21.
RowenTS, GaitherTW, AwadMA, et al.Pubic hair grooming prevalence and motivation among women in the United States. JAMA Dermatol, 2016; 152(10):1106–1113.
22.
HaysRD, LiuH, KapteynA. Use of Internet panels to conduct surveys. Behav Res Methods, 2015; 47(3):685–690.
23.
HeckmanCJ, DarlowS, ManneSL, et al.Correspondence and correlates of couples' skin cancer screening. JAMA Dermatol, 2013; 149(7):825–830.
24.
WilliamsHC, BurneyPG, PembrokeAC, et al. The U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis. III. Independent hospital validation. Br J Dermatol, 1994; 131(3):406–416.
25.
VakhariaPP, ChopraR, SacotteR, et al.Validation of patient-reported global severity of atopic dermatitis in adults. Allergy, 2018; 73(2):451–458.
26.
SilverbergJI, Chiesa FuxenchZC, GelfandJM, et al.Content and construct validity, predictors, and distribution of self-reported atopic dermatitis severity in US adults. Ann Allergy Asthma Immunol, 2018; 121(6):729–734.e724.
27.
StalderJF, BarbarotS, WollenbergA, et al.Patient-Oriented SCORAD (PO-SCORAD): a new self-assessment scale in atopic dermatitis validated in Europe. Allergy, 2011; 66(8):1114–1121.
28.
SilverbergJI, MargolisDJ, BoguniewiczM, et al.Validation of five patient-reported outcomes for atopic dermatitis severity in adults. Br J Dermatol, 2020; 182(1):104–111.
29.
SilverbergJI, LeiD, YousafM, et al.Comparison of Patient-Oriented Eczema Measure and Patient-Oriented Scoring Atopic Dermatitis vs Eczema Area and Severity Index and other measures of atopic dermatitis: a validation study. Ann Allergy Asthma Immunol, 2020; 125(1):78–83.
30.
CharmanCR, VennAJ, RavenscroftJC, et al.Translating Patient-Oriented Eczema Measure (POEM) scores into clinical practice by suggesting severity strata derived using anchor-based methods. Br J Dermatol, 2013; 169(6):1326–1332.
31.
SilverbergJI, GelfandJM, MargolisDJ, et al.Pain is a common and burdensome symptom of atopic dermatitis in United States adults. J Allergy Clin Immunol Pract, 2019; 7:2699–2706.e7.
32.
RogersA, DeLongLK, ChenSC. Clinical meaning in skin-specific quality of life instruments: a comparison of the Dermatology Life Quality Index and Skindex banding systems. Dermatol Clin, 2012; 30(2):333–342, x.
33.
BasraMK, FenechR, GattRM, et al.The Dermatology Life Quality Index 1994–2007: a comprehensive review of validation data and clinical results. Br J Dermatol, 2008; 159(5):997–1035.
34.
JenkinsonC, LayteR. Development and testing of the UK SF-12 (Short Form Health Survey). J Health Serv Res Policy, 1997; 2(1):14–18.
35.
WareJJr., KosinskiM, KellerSD.A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care, 1996; 34(3):220–233.
36.
SilverbergJI, GelfandJM, MargolisDJ, et al.Measurement properties of the Hospital Anxiety and Depression Scale used in atopic dermatitis in adults. J Invest Dermatol, 2019; 139(6):1388–1391.
37.
WittkowskiA, RichardsHL, GriffithsCE, et al.The impact of psychological and clinical factors on quality of life in individuals with atopic dermatitis. J Psychosom Res, 2004; 57(2):195–200.
38.
ZigmondAS, SnaithRP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand, 1983; 67(6):361–370.
39.
KaracanI, ThornbyJI, AnchM, et al.Prevalence of sleep disturbance in a primarily urban Florida County. Soc Sci Med, 1976; 10(5):239–244.
40.
DoiY, MinowaM, OkawaM, et al.Prevalence of sleep disturbance and hypnotic medication use in relation to sociodemographic factors in the general Japanese adult population. J Epidemiol, 2000; 10(2):79–86.
41.
SchroeckJL, FordJ, ConwayEL, et al.Review of safety and efficacy of sleep medicines in older adults. Clin Ther, 2016; 38(11):2340–2372.
42.
CamffermanD, KennedyJD, GoldM, et al.Eczema and sleep and its relationship to daytime functioning in children. Sleep Med Rev, 2010; 14(6):359–369.
43.
GuptaMA, GuptaAK. Sleep-wake disorders and dermatology. Clin Dermatol, 2013; 31(1):118–126.
44.
BenderBG, LeungDY. Sleep disorders in patients with asthma, atopic dermatitis, and allergic rhinitis. J Allergy Clin Immunol, 2005; 116(6):1200–1201.
45.
HillmanDR, LackLC. Public health implications of sleep loss: the community burden. Med J Aust, 2013; 199(8):S7–S10.
46.
RomanosM, GerlachM, WarnkeA, et al.Association of attention-deficit/hyperactivity disorder and atopic eczema modified by sleep disturbance in a large population-based sample. J Epidemiol Community Health, 2010; 64(3):269–273.
47.
SchmittJ, ChenCM, ApfelbacherC, et al.Infant eczema, infant sleeping problems, and mental health at 10 years of age: the prospective birth cohort study LISAplus. Allergy, 2011; 66(3):404–411.
48.
VgontzasAN, LiaoD, BixlerEO, et al.Insomnia with objective short sleep duration is associated with a high risk for hypertension. Sleep, 2009; 32(4):491–497.
49.
FerrieJE, KivimakiM, AkbaralyTN, et al.Change in sleep duration and type 2 diabetes: the Whitehall II study. Diabetes Care, 2015; 38(8):1467–1472.
50.
SpiegelK, KnutsonK, LeproultR, et al.Sleep loss: a novel risk factor for insulin resistance and type 2 diabetes. J Appl Physiol (1985), 2005; 99(5):2008–2019.
51.
VgontzasAN, LiaoD, PejovicS, et al.Insomnia with objective short sleep duration is associated with type 2 diabetes: a population-based study. Diabetes Care, 2009; 32(11):1980–1985.
52.
KobayashiD, TakahashiO, DeshpandeGA, et al.Association between weight gain, obesity, and sleep duration: a large-scale 3-year cohort study. Sleep Breath, 2012; 16(3):829–833.
53.
Navarro-SoleraM, Carrasco-LunaJ, Pin-ArboledasG, et al.Short sleep duration is related to emerging cardiovascular risk factors in obese children. J Pediatr Gastroenterol Nutr, 2015; 61(5):571–576.
54.
WatanabeM, KikuchiH, TanakaK, et al.Association of short sleep duration with weight gain and obesity at 1-year follow-up: a large-scale prospective study. Sleep, 2010; 33(2):161–167.
55.
BadranM, YassinBA, FoxN, et al.Epidemiology of sleep disturbances and cardiovascular consequences. Can J Cardiol, 2015; 31(7):873–879.
56.
SabanayagamC, ShankarA. Sleep duration and cardiovascular disease: results from the National Health Interview Survey. Sleep, 2010; 33(8):1037–1042.
57.
SilverbergJI, LeiD, YousafM, et al.Association of atopic dermatitis severity with cognitive function in adults. J Am Acad Dermatol, 2020; 83(5):1349–1359.
58.
GargN, SilverbergJI. Association between childhood allergic disease, psychological comorbidity, and injury requiring medical attention. Ann Allergy Asthma Immunol, 2014; 112(6):525–532.
59.
KwaMC, SilverbergJI. Association between inflammatory skin disease and cardiovascular and cerebrovascular co-morbidities in US adults: analysis of nationwide inpatient sample data. Am J Clin Dermatol, 2017; 18:813–823.
60.
SilverbergJI.Selected comorbidities of atopic dermatitis: atopy, neuropsychiatric, and musculoskeletal disorders. Clin Dermatol, 2017; 35(4):360–366.
61.
SilverbergJI.Comorbidities and the impact of atopic dermatitis. Ann Allergy Asthma Immunol, 2019; 123(2):144–151.
62.
SilverbergJI, SimpsonEL. Association between severe eczema in children and multiple comorbid conditions and increased healthcare utilization. Pediatr Allergy Immunol, 2013; 24(5):476–486.
63.
SilverbergJI.Association between adult atopic dermatitis, cardiovascular disease, and increased heart attacks in three population-based studies. Allergy, 2015; 70(10):1300–1308.
64.
SilverbergJI.Role of childhood obesity in atopic dermatitis. Exper Rev Dermatol, 2011; 6(6):635–642.
65.
SilverbergJI, BeckerL, KwasnyM, et al.Central obesity and high blood pressure in pediatric patients with atopic dermatitis. JAMA Dermatol, 2015; 151(2):144–152.
66.
SilverbergJI, KleimanE, Lev-TovH, et al.Association between obesity and atopic dermatitis in childhood: a case-control study. J Allergy Clin Immunol, 2011; 127(5):1180–1186.e1181.
67.
SilverbergJI, SilverbergNB, Lee-WongM. Association between atopic dermatitis and obesity in adulthood. Br J Dermatol, 2012; 166(3):498–504.
68.
SilverbergJI, SimpsonEL. Association between obesity and eczema prevalence, severity and poorer health in US adolescents. Dermatitis, 2014; 25(4):172–181.
69.
ZhangA, SilverbergJI. Association of atopic dermatitis with being overweight and obese: a systematic review and metaanalysis. J Am Acad Dermatol, 2015; 72(4):606–616.e604.
70.
BadiaX, MascaroJM, LozanoR. Measuring health-related quality of life in patients with mild to moderate eczema and psoriasis: clinical validity, reliability and sensitivity to change of the DLQI. The Cavide Research Group. Br J Dermatol, 1999; 141(4):698–702.
71.
CoutanceauC, StalderJF. Analysis of correlations between patient-oriented SCORAD (PO-SCORAD) and other assessment scores of atopic dermatitis severity and quality of life. Dermatology, 2014; 229(3):248–255.
72.
HolmEA, WulfHC, StegmannH, et al.Life quality assessment among patients with atopic eczema. Br J Dermatol, 2006; 154(4):719–725.
73.
HerdRM, TidmanMJ, RutaDA, et al.Measurement of quality of life in atopic dermatitis: correlation and validation of two different methods. Br J Dermatol, 1997; 136(4):502–507.
74.
FinlayAY, KhanGK. Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use. Clin Exp Dermatol, 1994; 19(3):210–216.
75.
JobanputraR, BachmannM. The effect of skin diseases on quality of life in patients from different social and ethnic groups in Cape Town, South Africa. Int J Dermatol, 2000; 39(11):826–831.
76.
HolmEA, EsmannS, JemecGB. Does visible atopic dermatitis affect quality of life more in women than in men?. Gend Med, 2004; 1(2):125–130.
77.
TwissJ, MeadsDM, PrestonEP, et al.Can we rely on the Dermatology Life Quality Index as a measure of the impact of psoriasis or atopic dermatitis?. J Invest Dermatol, 2012; 132(1):76–84.
78.
ChalmersJR, SchmittJ, ApfelbacherC, et al.Report from the Third International Consensus Meeting to Harmonise Core Outcome Measures for Atopic Eczema/Dermatitis Clinical Trials (HOME). Br J Dermatol, 2014; 171(6):1318–1325.
79.
ChalmersJR, SimpsonE, ApfelbacherCJ, et al.Report from the Fourth International Consensus Meeting to Harmonize Core Outcome Measures for Atopic Eczema/Dermatitis Clinical Trials (HOME initiative). Br J Dermatol, 2016; 175(1):69–79.
80.
GerbensLA, ChalmersJR, RogersNK, et alHarmonising Outcome Measures for Eczema (HOME) initiative. Reporting of symptoms in randomized controlled trials of atopic eczema treatments: a systematic review. Br J Dermatol, 2016; 175(4):678–686.
81.
GerbensLA, PrinsenCA, ChalmersJR, et al.Evaluation of the measurement properties of symptom measurement instruments for atopic eczema: a systematic review. Allergy, 2017; 72(1):146–163.
82.
HeinlD, ChalmersJ, NankervisH, et al.Eczema trials: quality of life instruments used and their relation to patient-reported outcomes. a systematic review. Acta Derm Venereol, 2016; 96(5):596–601.
83.
HeinlD, PrinsenCA, DeckertS, et al.Measurement properties of adult quality-of-life measurement instruments for eczema: a systematic review. Allergy, 2016; 71(3):358–370.
84.
HeinlD, PrinsenCAC, SachT, et al.Measurement properties of quality-of-life measurement instruments for infants, children and adolescents with eczema: a systematic review. Br J Dermatol, 2017; 176(4):878–889.
85.
SchmittJ, Williams HHOME DevelopmentGroup. Harmonising Outcome Measures for Eczema (HOME). Report from the First International Consensus Meeting (HOME 1), 24 July 2010, Munich, Germany. Br J Dermatol, 2010; 163(6):1166–1168.
86.
LeiD, YousafM, JanmohamedSR, et al.Validation of four single-item patient-reported assessments of sleep in adult atopic dermatitis patients. Ann Allergy Asthma Immunol, 2020; 124:261–266.
87.
SilverbergJI, GelfandJM, MargolisDJ, et al.Validation and interpretation of Short Form 12 and comparison with Dermatology Life Quality Index in atopic dermatitis in adults. J Invest Dermatol, 2019; 139(10):2090–2097.e3.
88.
PatelKR, SingamV, VakhariaPP, et al.Measurement properties of three assessments of burden used in atopic dermatitis in adults. Br J Dermatol, 2019; 180(5):1083–1089.
